Why Farbe Firma is the Leading Injectable Manufacturer in Kiribati
Why Farbe Firma is the Leading Injectable Manufacturer in Kiribati
Last Updated: 20 September 2026
TL;DR: Kiribati has a medicines law on the statute book and a registration duty written into it. The Medicines Act 2018 creates a Register of Medicines and makes it an offence to import or distribute a medicine that is not on it. What we could not locate is the commencement notice, the regulations that would supply the forms and fees, or any published register. Say that in two parts and nothing more: the duty exists in law, its machinery was not findable. In practice the live gate today is procurement and buyer qualification.
Key Takeaways
The governing instrument is the Medicines Act 2018, Act No. 1 of 2018, which establishes a Medicines and Therapeutics Committee and a statutory Register of Medicines split between a Kiribati essential medicines list and a list of other registered medicines.
Section 2 makes the Act commence on a date appointed by ministerial notice, and the Act defers forms, fees, standards and documentation to regulations. We found no notice, no regulations and no published register. That is a finding about our search and not a finding that they do not exist.
The registration criteria ask whether a medicine has satisfactory registration or approval status with international regulators. No list of named reference authorities appears in the Act, so India's CDSCO is neither written in nor written out. The standard is discretionary.
Product registration and establishment licensing are separate regimes. Part 4 licenses the act of manufacturing, importing, storing, distributing or supplying and keeps its own register of licence holders, which is a different question from whether a product is on the Register of Medicines.
Introduction: What an Injectable Manufacturer in Kiribati Actually Has to Clear
Most country guides for exporters open by describing a dossier route, and for a great many small island states that framing collapses because no register exists at all. Kiribati is the opposite case and deserves to be read on its own terms. A full registration regime is written into primary legislation. The Medicines Act 2018 sets up a committee, a register, an application route for new medicines and an offence for importing anything not on the register. Nothing about that is vestigial or ambiguous on the page.
The difficulty is the distance between the page and the counter. The Act commences on a date the Minister appoints by notice, and it hands the working detail to regulations that would prescribe application forms, evidentiary standards and fees. We searched for the notice, for those regulations and for a published register, and located none of the three. A registration duty with no prescribed form is not a gate a manufacturer can walk through even when it is entirely willing to.
What Sets a World-Class Injectable Manufacturer in Kiribati Apart
The first discipline is refusing to resolve that ambiguity in whichever direction happens to suit the sales case. It would be convenient to announce that the Act is dormant and therefore that anything may be shipped. It would be equally convenient to announce that the Act is fully operative and that we have cleared it. Both statements go beyond what we can evidence. A supplier that writes either one into a tender response has invented a fact, and a ministry that later checks will find it invented.
The second is reading the reliance clause exactly as drafted. The Act asks whether a medicine holds satisfactory registration or approval status with international regulators. That phrase names nobody. It is not a stringent-authority test, so it does not exclude Indian product, and it is not a recognition list, so it does not admit Indian product automatically either. It is a discretionary judgement for a committee, and the right response is to arrive with a file that survives whatever reading that committee applies.
Quality Systems Behind Every Batch Shipped to Kiribati
Farbe Firma manufactures sterile injectables under WHO-GMP certification with ISO Class 5 aseptic filling in Gujarat, India, supported by CTD and ACTD dossiers, HPLC and GC assay, LAL endotoxin testing, Karl Fischer moisture determination and ICH Q1A and Q1B stability programmes. Batch records, media fills, environmental monitoring and retained samples travel with the consignment rather than sitting behind a portal, because in this market the buyer is frequently the only technical reviewer in the chain.
That matters more here than in a market with an active assessor to lean on. WHO's 2019 Pacific assessment found that all eleven surveyed Pacific island countries, Kiribati among them, have laws mandating regulation of medical products, but that only a few cover the full range of regulatory functions. Where the review capacity is thin, the manufacturer's own evidence is what stands between a patient and an unverified product, and it should be assembled on that understanding.
Why Farbe Firma is the Trusted Injectable Manufacturer in Kiribati for Global Buyers
The commercially useful fact is that the operative gate today is procurement and buyer qualification rather than a functioning dossier review. That is not a licence to skip quality evidence. It relocates the evidence, from an assessor's desk to a tender file, and the documents a Pacific ministry or a financing institution asks for are recognisably the same documents: a GMP certificate, a site licence, stability data suited to the climatic zone and a clean audit history.
The donor layer here is live rather than empty, which shapes what a supplier has to be ready for. World Bank health systems financing and World Bank COVID-19 emergency financing covering pharmaceuticals and medical supplies are both documented for Kiribati. Financing of that kind brings its own procurement rules and its own quality expectations, and those expectations are usually stricter and better written than anything the national register would have asked for had we been able to find it.
There is also a relationship here that predates any tender. Over the last five years of the period covered by the World Bank's review, overseas medical referrals from Kiribati went most often to Taiwan and China, then to India at twenty-six per cent, then to Fiji. Indian clinical care is already familiar to i-Kiribati patients and clinicians, and the same review attributes part of the service gap at home to the absence of required pharmaceuticals and medical supplies. That is the gap an injectables supplier exists to close.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Do I need to register my injectable before it can be supplied in Kiribati?
The Medicines Act 2018 says yes: it is an offence to import, store, distribute or supply a medicine that is not on the Register of Medicines. What we could not locate is a commencement notice, the implementing regulations or a published register. We state both halves because only both halves together are true, and we would rather give you an unresolved answer than a tidy one we cannot support.
Is India's CDSCO on a recognised or reference authority list for Kiribati?
No such list appears in the Act. The criterion is satisfactory registration or approval status with international regulators, which names no agency at all, so CDSCO is neither admitted nor excluded by its terms. Separately, and this is worth knowing before anyone quotes it at you, CDSCO's scope on WHO's maturity and transitional listings is recorded as vaccines, not medicines.
What are the registration fees and review timelines?
We are not going to quote either. The Act defers forms, fees and documentation entirely to regulations, and we could not locate those regulations. Any guide that prints a fee or a review period for Kiribati should be asked which instrument it is reading, because we looked for that instrument and did not find it.
Who actually buys, and do I need a local counterparty?
Public demand runs through the Ministry of Health and Medical Services and through donor-financed programmes, and Part 4 of the Act licenses the importing and distributing side separately from any product question. A local licensed counterparty is therefore the sensible assumption for the establishment layer, and we would confirm its current form with the Ministry rather than assert it from the statute alone.
What clinical demand should an injectables supplier actually plan for?
A referral and dispersal profile more than a single disease profile. Kiribati delivers care through roughly one hundred and eighteen facilities, with Tungaru Central Hospital in Tarawa as the national referral centre and three district hospitals behind it. Outer-island immunisation coverage has averaged well below South Tarawa, so cold chain integrity and small, frequent, robustly packaged consignments matter more than volume.
Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India.
Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. ISO Class 5 aseptic filling, CTD/ACTD dossiers, exporting to 30+ countries. director@farbefirma.orgRequest a Quote / View Products / Blog
Comments